# Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

> **NCT01659138** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 28 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** SAR339658
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01659138
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-06
- **Final completion:** 2016-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.
- **Last updated:** 2016-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01659138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01659138, "Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01659138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*